STAT+: Servier’s $1.55 billion muscular dystrophy drug fails first major test
The French pharma Servier said Tuesday that an experimental drug it purchased in June for $1.55 billion in cash, plus about $1 billion more in potential milestones, failed to slow a rare form of muscular dystrophy in a long placebo-controlled…
ImpactNotable
Published8 h ago (Tue, 03 Nov 2026 20:53:20 GMT)
AuthorJason Mast
MoreLess
Impact score37/100
RatingProbability of 29%.
RegionsGlobal
Retrievedvia rss
ClassifiedTue, 03 Nov 2026 21:01:17 GMT by classifier